Allakos Investor Relations Material
Latest events
Study Result
Allakos
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Allakos Inc
Access all reports
Allakos Inc. is a biopharmaceutical company focused on the development of antibody-based therapies for the treatment of allergic, inflammatory, and proliferative diseases. The company's primary approach involves targeting specific immune cells and inflammatory pathways that contribute to diseases such as eosinophilic gastritis and other related gastrointestinal and inflammatory conditions. Allakos leverages proprietary antibody technologies to create potential therapeutic options aimed at improving outcomes for patients with limited treatment choices. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
ALLK
Country
🇺🇸 United States